Long-term outcome and bridging success of patients evaluated and bridged to lung transplantation on the ICU.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
05 2022
Historique:
received: 02 06 2021
revised: 13 01 2022
accepted: 14 01 2022
pubmed: 23 3 2022
medline: 27 4 2022
entrez: 22 3 2022
Statut: ppublish

Résumé

Evaluating and bridging patients to lung transplantation (LTx) on the intensive care unit (ICU) remains controversial, especially without a previous waitlist status. Long term outcome data after LTx from ICU remains scarce. We compared long-term survival and development of chronic lung allograft dysfunction (CLAD) in elective and LTx from ICU, with or without previous waitlist status. Patients transplanted between 2004 and 2018 in 2 large academic Dutch institutes were included. Long-term survival and development of CLAD was compared in patients who received an elective LTx (ELTx), those bridged and transplanted from the ICU with a previous listing status (BTT), and in patients urgently evaluated and bridged on ICU (EBTT). A total of 582 patients underwent a LTx, 70 (12%) from ICU, 39 BTT and 31 EBTT. Patients transplanted from ICU were younger than ELTx (46 vs 51 years) and were bridged with mechanical ventilation (n = 42 (60%)), extra corporeal membrane oxygenation (n = 28 (40%)), or both (n = 21/28). Bridging success was 48% in the BTT group and 72% in the EBTT group. Patients bridged to LTx on ICU had similar 1 and 5 year survival (86.8% and 78.4%) compared to elective LTx (86.8% and 71.9%). This was not different between the BTT and EBTT group. 5 year CLAD free survival was not different in patients transplanted from ICU vs ELTx. Patients bridged to LTx on the ICU with and without prior listing status had excellent short and long-term patient and graft outcomes, and was similar to patients electively transplanted.

Sections du résumé

BACKGROUND
Evaluating and bridging patients to lung transplantation (LTx) on the intensive care unit (ICU) remains controversial, especially without a previous waitlist status. Long term outcome data after LTx from ICU remains scarce. We compared long-term survival and development of chronic lung allograft dysfunction (CLAD) in elective and LTx from ICU, with or without previous waitlist status.
METHODS
Patients transplanted between 2004 and 2018 in 2 large academic Dutch institutes were included. Long-term survival and development of CLAD was compared in patients who received an elective LTx (ELTx), those bridged and transplanted from the ICU with a previous listing status (BTT), and in patients urgently evaluated and bridged on ICU (EBTT).
RESULTS
A total of 582 patients underwent a LTx, 70 (12%) from ICU, 39 BTT and 31 EBTT. Patients transplanted from ICU were younger than ELTx (46 vs 51 years) and were bridged with mechanical ventilation (n = 42 (60%)), extra corporeal membrane oxygenation (n = 28 (40%)), or both (n = 21/28). Bridging success was 48% in the BTT group and 72% in the EBTT group. Patients bridged to LTx on ICU had similar 1 and 5 year survival (86.8% and 78.4%) compared to elective LTx (86.8% and 71.9%). This was not different between the BTT and EBTT group. 5 year CLAD free survival was not different in patients transplanted from ICU vs ELTx.
CONCLUSION
Patients bridged to LTx on the ICU with and without prior listing status had excellent short and long-term patient and graft outcomes, and was similar to patients electively transplanted.

Identifiants

pubmed: 35314097
pii: S1053-2498(22)00035-3
doi: 10.1016/j.healun.2022.01.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-598

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure statement The authors have no conflicts of interest to declare.

Auteurs

C Tji Gan (CT)

Department of Respiratory Diseases, Tuberculosis and Lung Transplantation, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: c.t.gan@umcg.nl.

Rogier A S Hoek (RAS)

Department of Pulmonary Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Wim van der Bij (W)

Department of Respiratory Diseases, Tuberculosis and Lung Transplantation, University Medical Center Groningen, Groningen, The Netherlands.

Caroline Van De Wauwer (C)

Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, The Netherlands.

Michiel E Erasmus (ME)

Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, The Netherlands.

Annemiek Oude Lansink-Hartgring (A)

Department of Critical Care, University Medical Center Groningen, Groningen, The Netherlands.

Joep M Droogh (JM)

Department of Critical Care, University Medical Center Groningen, Groningen, The Netherlands.

Leonard Seghers (L)

Department of Pulmonary Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Bas J Mathot (BJ)

Department of Pulmonary Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Edris A F Mahtab (EAF)

Department of Cardiothoracic Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Jos A Bekkers (JA)

Department of Cardiothoracic Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Dinis Dos Reis Miranda (D)

Department of Intensive Care Medicine, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Erik A M Verschuuren (EAM)

Department of Respiratory Diseases, Tuberculosis and Lung Transplantation, University Medical Center Groningen, Groningen, The Netherlands.

Merel E Hellemons (ME)

Department of Pulmonary Medicine, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH